Annual CFF
$7.36 M
+$7.05 M+2320.72%
March 1, 2024
Summary
- As of February 8, 2025, GRCE annual cash flow from financing activities is $7.36 million, with the most recent change of +$7.05 million (+2320.72%) on March 1, 2024.
- During the last 3 years, GRCE annual CFF has fallen by -$52.13 million (-87.63%).
- GRCE annual CFF is now -87.63% below its all-time high of $59.49 million, reached on March 1, 2021.
Performance
GRCE Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$0.00
NaN%
September 1, 2024
Summary
- As of February 8, 2025, GRCE quarterly cash flow from financing activities is $0.00
- Over the past year, GRCE quarterly CFF has stayed the same.
- GRCE quarterly CFF is now -100.00% below its all-time high of $35.59 million, reached on December 1, 2018.
Performance
GRCE Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$0.00
NaN%
September 1, 2024
Summary
- As of February 8, 2025, GRCE TTM cash flow from financing activities is $0.00
- Over the past year, GRCE TTM CFF has dropped by -$7.36 million (-100.00%).
- GRCE TTM CFF is now -100.00% below its all-time high of $59.49 million, reached on March 1, 2021.
Performance
GRCE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
GRCE Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2320.7% | 0.0% | -100.0% |
| 3 y3 years | -87.6% | -100.0% | -100.0% |
| 5 y5 years | -83.9% | -100.0% | -100.0% |
GRCE Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -87.6% | -100.0% | -100.0% | at low | -100.0% | at low |
| 5 y | 5-year | -87.6% | -100.0% | -100.0% | +100.0% | -100.0% | at low |
| alltime | all time | -87.6% | >+9999.0% | -100.0% | +100.0% | -100.0% | +100.0% |
Grace Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Mar 2024 | $7.36 M(+2320.7%) | $0.00(0.0%) | $7.36 M(0.0%) |
| Dec 2023 | - | $0.00(-100.0%) | $7.36 M(0.0%) |
| Sep 2023 | - | $7.36 M(>+9900.0%) | $7.36 M(+2320.7%) |
| Mar 2023 | $304.00 K(>+9900.0%) | $0.00(0.0%) | $304.00 K(0.0%) |
| Dec 2022 | - | $0.00(-100.0%) | $304.00 K(0.0%) |
| Sep 2022 | - | $109.00 K(-44.1%) | $304.00 K(+55.9%) |
| Jun 2022 | - | $195.00 K(>+9900.0%) | $195.00 K(>+9900.0%) |
| Mar 2022 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Dec 2021 | - | $0.00(0.0%) | $34.68 M(-36.3%) |
| Sep 2021 | - | $0.00(0.0%) | $54.42 M(-5.9%) |
| Jun 2021 | - | $0.00(-100.0%) | $57.85 M(-2.7%) |
| Mar 2021 | $59.49 M(+351.3%) | $34.68 M(+75.6%) | $59.49 M(+145.0%) |
| Dec 2020 | - | $19.75 M(+475.3%) | $24.28 M(+108.4%) |
| Sep 2020 | - | $3.43 M(+109.9%) | $11.65 M(-21.2%) |
| Jun 2020 | - | $1.64 M(-408.5%) | $14.78 M(+12.1%) |
| Mar 2020 | $13.18 M(-71.1%) | -$530.00 K(-107.4%) | $13.18 M(-16.7%) |
| Dec 2019 | - | $7.12 M(+8.5%) | $15.83 M(-64.3%) |
| Sep 2019 | - | $6.56 M(>+9900.0%) | $44.31 M(+17.2%) |
| Jun 2019 | - | $34.00 K(-98.4%) | $37.79 M(-17.3%) |
| Mar 2019 | $45.69 M(+417.3%) | $2.12 M(-94.0%) | $45.69 M(+5.5%) |
| Dec 2018 | - | $35.59 M(>+9900.0%) | $43.30 M(+152.5%) |
| Sep 2018 | - | $44.90 K(-99.4%) | $17.15 M(+0.4%) |
| Jun 2018 | - | $7.94 M(-3074.4%) | $17.09 M(+93.5%) |
| Mar 2018 | $8.83 M(+71.6%) | -$266.80 K(-102.8%) | $8.83 M(-2.9%) |
| Dec 2017 | - | $9.44 M(<-9900.0%) | $9.10 M(-2771.5%) |
| Sep 2017 | - | -$16.50 K(-94.9%) | -$340.60 K(+4.6%) |
| Jun 2017 | - | -$323.70 K(>+9900.0%) | -$325.60 K(+2547.2%) |
| Mar 2017 | $5.15 M | - | - |
| Nov 2016 | - | -$400.00(-73.3%) | -$12.30 K(-3.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Aug 2016 | - | -$1500.00(-85.0%) | -$12.70 K(+10.4%) |
| May 2016 | - | -$10.00 K(+2400.0%) | -$11.50 K(+400.0%) |
| Feb 2016 | -$2200.00(-106.0%) | -$400.00(-50.0%) | -$2300.00(-63.5%) |
| Nov 2015 | - | -$800.00(+166.7%) | -$6300.00(-25.9%) |
| Aug 2015 | - | -$300.00(-62.5%) | -$8500.00(-14.1%) |
| May 2015 | - | -$800.00(-81.8%) | -$9900.00(-126.9%) |
| Feb 2015 | $36.80 K(-99.8%) | -$4400.00(+46.7%) | $36.80 K(-99.8%) |
| Nov 2014 | - | -$3000.00(+76.5%) | $21.59 M(-2.3%) |
| Aug 2014 | - | -$1700.00(-103.7%) | $22.10 M(-1.6%) |
| May 2014 | - | $45.90 K(-99.8%) | $22.46 M(+0.1%) |
| Feb 2014 | $22.44 M(>+9900.0%) | $21.55 M(+4187.7%) | $22.44 M(+2007.4%) |
| Nov 2013 | - | $502.60 K(+38.1%) | $1.06 M(+88.1%) |
| Aug 2013 | - | $364.00 K(+1825.9%) | $566.00 K(+147.9%) |
| May 2013 | - | $18.90 K(-89.4%) | $228.30 K(+3.1%) |
| Feb 2013 | $221.50 K(-97.8%) | $179.10 K(+4377.5%) | $221.50 K(-90.5%) |
| Nov 2012 | - | $4000.00(-84.8%) | $2.33 M(-76.6%) |
| Aug 2012 | - | $26.30 K(+117.4%) | $9.94 M(-0.1%) |
| May 2012 | - | $12.10 K(-99.5%) | $9.95 M(+0.1%) |
| Feb 2012 | $9.94 M(+126.2%) | $2.29 M(-70.0%) | $9.94 M(+26.9%) |
| Nov 2011 | - | $7.62 M(>+9900.0%) | $7.83 M(+76.8%) |
| Aug 2011 | - | $36.10 K(-9125.0%) | $4.43 M(+0.8%) |
| May 2011 | - | -$400.00(-100.2%) | $4.39 M(-0.0%) |
| Feb 2011 | $4.40 M(+5578.9%) | $178.40 K(-95.8%) | $4.40 M(+2.4%) |
| Nov 2010 | - | $4.22 M(<-9900.0%) | $4.29 M(+5497.1%) |
| Aug 2010 | - | -$200.00(-140.0%) | $76.70 K(-1.5%) |
| May 2010 | - | $500.00(-99.3%) | $77.90 K(+0.6%) |
| Feb 2010 | $77.40 K | $76.00 K(>+9900.0%) | $77.40 K(+5428.6%) |
| Nov 2009 | - | $400.00(-60.0%) | $1400.00(+40.0%) |
| Aug 2009 | - | $1000.00(>+9900.0%) | $1000.00(>+9900.0%) |
| May 2009 | - | $0.00 | $0.00 |
FAQ
- What is Grace Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Grace Therapeutics?
- What is Grace Therapeutics annual CFF year-on-year change?
- What is Grace Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Grace Therapeutics?
- What is Grace Therapeutics quarterly CFF year-on-year change?
- What is Grace Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Grace Therapeutics?
- What is Grace Therapeutics TTM CFF year-on-year change?
What is Grace Therapeutics annual cash flow from financing activities?
The current annual CFF of GRCE is $7.36 M
What is the all time high annual CFF for Grace Therapeutics?
Grace Therapeutics all-time high annual cash flow from financing activities is $59.49 M
What is Grace Therapeutics annual CFF year-on-year change?
Over the past year, GRCE annual cash flow from financing activities has changed by +$7.05 M (+2320.72%)
What is Grace Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of GRCE is $0.00
What is the all time high quarterly CFF for Grace Therapeutics?
Grace Therapeutics all-time high quarterly cash flow from financing activities is $35.59 M
What is Grace Therapeutics quarterly CFF year-on-year change?
Over the past year, GRCE quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is Grace Therapeutics TTM cash flow from financing activities?
The current TTM CFF of GRCE is $0.00
What is the all time high TTM CFF for Grace Therapeutics?
Grace Therapeutics all-time high TTM cash flow from financing activities is $59.49 M
What is Grace Therapeutics TTM CFF year-on-year change?
Over the past year, GRCE TTM cash flow from financing activities has changed by -$7.36 M (-100.00%)